Reuters - Biogen Idec Inc's said on Wednesday its experimental multiple sclerosis drug BG-12 met the main goal of a closely watched clinical trial, sending its shares up 9 percent.
You are here:
Health 
Diseases & Conditions Biogen MS drug BG-12 meets goal of second trial
(Reuters)
Diseases & Conditions Biogen MS drug BG-12 meets goal of second trial
(Reuters)
